Ernst-Günter Afting
Direktor/Vorstandsmitglied bei BioMedCredit AG
Profil
Ernst-Günter Afting currently works at Olympus Europa GmbH, as Director, BioMedCredit AG, as Member-Supervisory Board from 2012, and Olympus Europa Holding GmbH, as Member-Supervisory Board.
Dr. Afting also formerly worked at Hoechst AG, as Chairman & CEO-Pharmaceutical Division in 1993, Roussel Uclaf SA, as President & Chief Executive Officer from 1993 to 1995, GSF-National Research Center for Environment & Health GmbH, as President & Chief Executive Officer from 1995 to 2006, Intercell AG, as Vice Chairman-Supervisory Board from 2012 to 2013, Avontec GmbH, as Chairman-Supervisory Board in 2010, Biovertis AG, as Chairman-Supervisory Board, Quidel Corp., as Director, Titan Pharmaceuticals, Inc., as Director, Sequenom, Inc., as Independent Director from 2012 to 2014, Quikbyte Software, Inc., as Director, Behringwerke AG, as Director in 1989, Enanta Pharmaceuticals, Inc., as Independent Class III Director from 2012 to 2017, Sorrento Therapeutics, Inc., as Independent Director from 2013 to 2014, and Retrotope, Inc., as Director.
Dr. Afting received his graduate degree and doctorate degree from the University of Freiburg and undergraduate degree from the University of Münster.
Aktive Positionen von Ernst-Günter Afting
| Unternehmen | Position | Beginn |
|---|---|---|
BioMedCredit AG
 BioMedCredit AG Investment ManagersFinance BioMedCredit AG provides capital in the form of repayable, interest-bearing loans to small- and mid-sized private companies in Switzerland. | Direktor/Vorstandsmitglied | 18.05.2011 |
| Olympus Europa Holding GmbH | Direktor/Vorstandsmitglied | - |
Olympus Europa GmbH
 Olympus Europa GmbH Medical DistributorsDistribution Services Part of Olympus Corp., Olympus Europa GmbH is a German company that creates customer-driven solutions for the medical, life sciences, and industrial equipment industries. The company is based in Hamburg, Germany and operates in dozens of countries all over the world. The company offers a comprehensive lineup of solutions for early diagnosis and minimally invasive therapy for a range of diseases. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Ernst-Günter Afting
| Unternehmen | Position | Ende |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 16.02.2017 |
| SEQUENOM, INC. | Direktor/Vorstandsmitglied | 10.06.2014 |
| SORRENTO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 30.01.2014 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Direktor/Vorstandsmitglied | 28.05.2013 |
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Vorsitzender | 16.06.2010 |
Ausbildung von Ernst-Günter Afting
| University of Freiburg | Doctorate Degree |
| University of Münster | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| TITAN PHARMACEUTICALS, INC. | Health Technology |
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 14 |
|---|---|
Quidel Corp.
 Quidel Corp. Medical SpecialtiesHealth Technology Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The firm products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA. | Health Technology |
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
Sequenom, Inc.
 Sequenom, Inc. Medical SpecialtiesHealth Technology Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in Burlington, NC. | Health Technology |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Olympus Europa GmbH
Olympus Europa GmbH Medical DistributorsDistribution Services Part of Olympus Corp., Olympus Europa GmbH is a German company that creates customer-driven solutions for the medical, life sciences, and industrial equipment industries. The company is based in Hamburg, Germany and operates in dozens of countries all over the world. The company offers a comprehensive lineup of solutions for early diagnosis and minimally invasive therapy for a range of diseases. | Distribution Services |
Quikbyte Software, Inc.
 Quikbyte Software, Inc. Financial ConglomeratesFinance The Company is develops and markets Computere Software.The Company was Founded in 1989 and it's Headquartered is in Miami,FL. | Finance |
Behringwerke AG
 Behringwerke AG Pharmaceuticals: OtherHealth Technology Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The company is based in Marburg, Germany. | Health Technology |
| Roussel Uclaf SA | Health Technology |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
Biovertis AG
 Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Health Technology |
| GSF-National Research Center for Environment & Health GmbH | |
BioMedCredit AG
BioMedCredit AG Investment ManagersFinance BioMedCredit AG provides capital in the form of repayable, interest-bearing loans to small- and mid-sized private companies in Switzerland. | Finance |
| Olympus Europa Holding GmbH | |
Retrotope, Inc.
 Retrotope, Inc. Pharmaceuticals: MajorHealth Technology Retrotope, Inc. operates as clinical-stage pharmaceutical company that develops drugs to treat degenerative diseases. It offers drugs and therapies to treat Parkinson’s, Alzheimer’s, mitochondrial myopathies and retinopathies diseases. The company was founded by Charles R. Cantor, Robert J. Molinari, and Mikhail S. Shchepinov in 2006 and is headquartered in Los Altos, CA. | Health Technology |
